S. Yesilkaya1, C. Acikel2, B. Fidanci3, A. Polat4, B. Sozeri5, N. Ayaz6, B. Makay7, D. Simsek8, N. Akinci9, G. Özçelik10, S. Kavukçu11, S. Emre12, O. Donmez13, A. Delibas14, S. Yüksel15, A. Berdeli16, H. Poyrazoglu17, M. Saldir18, K. Fidanci19, N. Çakar20, H. Peru21, S. Bakkaloglu22, Y. Tabel23, O. Sari24, U. Aydogan25, S. Ozenc26, G. Basbozkurt27, E. Unsal28, Ö. Kasapçopur29, F. Gok30, S. Ozen31, E. Demirkaya32; for FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology (FAVOR)
2015 Vol.33, N°6 ,Suppl.94 - PI 0156, PF 0162
To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients.
The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2–18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability.
One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach’s alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p<0.001). Also, a significant correlation between parents’ and children’s reports (r=0.781, p<0.001).
Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended.
PMID: 26393894 [PubMed]
Received: 08/09/2014 - Accepted : 05/06/2015 - In Press: 22/09/2015 - Published: 04/11/2015